Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARINET Extension: Lanreotide Autogel in Non-functioning Entero-pancreatic NET
NCT00842348Phase 3Completed
- Sponsor
- Ipsen
- Start
- Feb 2009
- Primary completion
- Dec 2015
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of lanreotide in Pancreatic neuroendocrine tumor (pNET), sponsored by Ipsen. Primary endpoint: Adverse Events. Started Feb 2009; status: completed.
02
Drugs
lanreotide
03
Conditions
Pancreatic neuroendocrine tumor (pNET)
Beyond the preview
Go deeper on NCT00842348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842348.